Oncoimmunology
Impact Factor Trend (2020–2026)
Clarivate IF trend for Oncoimmunology
SCImago Journal Rank citation prestige weighting
134 papers with at least that number of citations each
Aims & Scope
Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. We now create a new, high-profile journal, OncoImmunology, that specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies. OncoImmunology will accept high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses will be welcome.
Special Issues
Calls for PapersNo active Calls for Papers found for this journal.
WoS Categories & Quartiles
Detailed JCR / JCI category rankings and quartile breakdown from Clarivate
IMMUNOLOGY
ONCOLOGY
IMMUNOLOGY
ONCOLOGY
Annual Historical Statistics & Publications
Track annual publication volume, total citations, and Impact Factor evolution
SCImago & Scopus Journal Intelligence
Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact
Weighted prestige citation metric per document indexed in the Scopus database.
Average citations received per document published in the 2-year window.
Estimated Article Processing Charge for Open Access publication.
Scopus 3-Year Publication & Citation Window
Aggregated from Scopus database across the 3-year SJR evaluation window.
Societal Impact & Inclusivity (SCImago)
Citations in government and international policy documents
Percentage of female authors published in the journal
Real-world societal policy reach and author gender diversity tracked by SCImago.
Scopus Subject Categories
Journal Metrics & Citation Visualizations
Total Cites vs Self-Cites
Evaluation of scholarly independence and citation reach
Citations per Document
Citation metric windows across 2, 3, and 4 years
Chinese Academy of Sciences (CAS) Classification
Major / minor zone classification and CAS Early Warning List history
Academic Intelligence Overview & Context
ImpaQ AnalysisOncoimmunology (acronym: oncoimm, abbr: ONCOIMMUNOLOGY, ISSN: 2162-4011) is a peer-reviewed international scholarly journal in the field of ONCOLOGY, published by Landes Bioscience in United States. The periodical holds a Journal Impact Factor (JIF) of 6.20, ranking in quartile Q1 of Web of Science (SCIE), a Scopus SJR indicator of 2.438 (Q1), an H-index of 134.
The journal enforces rigorous peer evaluation with an annual output of approximately 218 scientific articles. In terms of accessibility and author fees, it operates under the Gold OA model with an estimated APC of $3,877 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.
Publishing & Editorial Information
Detailed publisher, peer-review turnaround, and publication cycle specifications
Similar Journals in Discipline
Journals in the same research field with comparable impact metrics